Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1731 to 1740 of 1911 total matches.

Anistreplase for Acute Coronary Thrombosis

   
The Medical Letter on Drugs and Therapeutics • Feb 23, 1990  (Issue 812)
in patients with acute myocardial infarction found that after 30 days, only 32 (6.4%) of 502 patients treated ...
Anistreplase (Eminase - SmithKline Beecham, Upjohn), a plasminogen activator also known as APSAC, was recently approved by the US Food and Drug Administration (FDA) for intravenous (IV) thrombolytic treatment of coronary thrombosis. Three other thrombolytic agents - intracoronary urokinase (Abbokinase) and intracoronary or intravenous streptokinase (Streptase; Kabikinase) and alteplase (TPA; Activase)- were previously approved for coronary thrombolysis (Medical Letter, 29:107, 1987).
Med Lett Drugs Ther. 1990 Feb 23;32(812):15-6 |  Show IntroductionHide Introduction

Desk-Top Systems For Office Chemistries

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990  (Issue 829)
are available and should be run once each day for each test. The instrument has been reported to maintain its ...
Four different desk-top systems are now widely used in physicians'; offices to measure blood chemistries. The Ektachem DT (Kodak) and Reflotron (Boehringer Mannheim), reviewed previously in The Medical Letter (volume 30, page 119, 1988; volume 31, page 90, 1989), resemble the Seralyzer (Miles Diagnostics) in cost; the Vision (Abbott), which is fully automated, is much more expensive.
Med Lett Drugs Ther. 1990 Oct 19;32(829):96-8 |  Show IntroductionHide Introduction

Intravenous Ciprofloxacin

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991  (Issue 850)
OF CIPROFLOXACIN AND SOME ALTERNATIVES Cost of One Days’ Drug Daily Dosage 1 Treatment 2 Amikacin − Amikin ...
Ciprofloxacin, previously available orally (Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use (Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Med Lett Drugs Ther. 1991 Aug 9;33(850):75-6 |  Show IntroductionHide Introduction

Tretinoin for Photodamaged Skin

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 1992  (Issue 866)
, on areas of skin usually not exposed to the sun, showed that four days’ application of sodium lauryl ...
Tretinoin (tret' i noyn; all-trans-retinoic acid; Retin-A), a derivative of vitamin A, has been used for years for topical treatment of acne. More recently, it has also been used to improve the appearance of skin damaged by chronic exposure to the sun, although not approved for this indication by the US Food and Drug Administration.
Med Lett Drugs Ther. 1992 Mar 20;34(866):28-9 |  Show IntroductionHide Introduction

Corneal Surgery for Myopia

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 1993  (Issue 907)
the course of the day, rarely requiring multiple pairs of glasses; both of these effects may be transient ...
Readers have inquired about the effectiveness and safety of operations on the cornea to correct refractive errors and restore normal vision without glasses or contact lenses. Several different operations are now being used for this purpose.
Med Lett Drugs Ther. 1993 Oct 15;35(907):95-6 |  Show IntroductionHide Introduction

Synagis Revisited

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2001  (Issue 1098)
born at 32 to 35 weeks who have additional risk factors for RSV infection such as day-care attendance ...
Palivizumab (Synagis - MedImmune), an injectable monoclonal antibody, has been marketed in the USA since 1999 for prevention of respiratory syncytial virus (RSV) disease in high-risk infants and children.
Med Lett Drugs Ther. 2001 Feb 19;43(1098):13-4 |  Show IntroductionHide Introduction

Formoterol (Foradil Aerolizer) For Asthma

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001  (Issue 1104)
µg/puff) * Cost for 30 days’ treatment with the lowest recommended adult dosage, according to AWP ...
Formoterol fumarate inhalation powder Foradil Aerolizer, a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced bronchospasm. The drug has been available in Europe for many years.
Med Lett Drugs Ther. 2001 May 14;43(1104):39-40 |  Show IntroductionHide Introduction

Tazarotene (Tazorac) for Acne

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002  (Issue 1132)
, alternate-day treatment with tazarotene gel 0.1% was as effective as daily treatment with adapalene gel 0.1 ...
Tazarotene (taz ar' oh teen, Tazorac - Allergan), an acetylinic retinoid marketed for treatment of psoriasis (Medical Letter 1997; 39:105), is also available as a 0.1% gel and cream for treatment of acne.
Med Lett Drugs Ther. 2002 Jun 10;44(1132):52-3 |  Show IntroductionHide Introduction

Dutasteride (Avodart) for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2002  (Issue 1146)
− Avodart (GlaxoSmithKline) 0.5 mg $74.77 Finasteride − Proscar (Merck) 5 mg 70.52 * Cost for 30 days ...
Dutasteride (Avodart - GlaxoSmithKline) is now available in the US for oral treatment of benign prostatic hyperplasia (BPH). It is similar to finasteride (Proscar - Merck), which has been marketed for this indication since 1992 and also, since 1998, for alopecia (Propecia - Medical Letter 1998; 40:25).
Med Lett Drugs Ther. 2002 Dec 23;44(1146):109-10 |  Show IntroductionHide Introduction

Conductive Keratoplasty (CK) for Presbyopia

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004  (Issue 1185)
pain, foreign body sensation and fluctuation in visual clarity for a few days or weeks. Correction ...
The ViewPoint CK System (Refractec) for conductive keratoplasty (CK), previously approved by the FDA as a device for treatment of hyperopia (farsightedness), was recently approved for treatment of presbyopia (age-associated loss of ability to view near objects).
Med Lett Drugs Ther. 2004 Jun 21;46(1185):49-50 |  Show IntroductionHide Introduction